Ottawa signs $40M deal with Saskatchewan to offer drug coverage for rare diseases
Advertisement
Read this article for free:
or
Already have an account? Log in here »
To continue reading, please subscribe:
Monthly Digital Subscription
$0 for the first 4 weeks*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*No charge for 4 weeks then price increases to the regular rate of $19.00 plus GST every four weeks. Offer available to new and qualified returning subscribers only. Cancel any time.
Monthly Digital Subscription
$4.75/week*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*Billed as $19 plus GST every four weeks. Cancel any time.
To continue reading, please subscribe:
Add Free Press access to your Brandon Sun subscription for only an additional
$1 for the first 4 weeks*
*Your next subscription payment will increase by $1.00 and you will be charged $16.99 plus GST for four weeks. After four weeks, your payment will increase to $23.99 plus GST every four weeks.
Read unlimited articles for free today:
or
Already have an account? Log in here »
Hey there, time traveller!
This article was published 10/01/2025 (337 days ago), so information in it may no longer be current.
SASKATOON – The Saskatchewan and federal governments have announced an agreement for coverage of select new drugs for rare diseases.
Ottawa says the plan is to invest more than $40 million to cover three drugs that treat certain cancers and a urinary issue.
The medicines are Poteligeo, Oxlumo and Epkinly.
The agreement is to also see Saskatchewan work with Ottawa and other provinces to develop a plan to improve screening and diagnostics for rare diseases.
Federal Health Minister Mark Holland says the deal helps the health system improve outcomes for those in Saskatchewan with rare diseases.